Kadcyla 100 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FSQS0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,915
Award facts
- Contract value 100% obligated
- $17,914.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $17,914.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Kadcyla 100 mg vials. This firm fixed-price delivery order, issued on January 13, 2026 with an ultimate completion date of February 4, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare operations.
DMS Pharmaceutical Group serves as a critical regional prime vendor contractor under the PPV-G GEN V program, which authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support military healthcare facilities worldwide. The company's establishment as a prime vendor under this contract, with a ceiling value of $499,999,999 through December 31, 2036, positions it as a key supplier within the federal pharmaceutical supply chain. This specific delivery order for Kadcyla—a therapeutic oncology agent—reflects DMS Pharmaceutical Group's demonstrated capability to fulfill the specialized pharmaceutical requirements of the Department of Defense medical system.
Quick answers
Who was awarded contract SPE2DR26FSQS0?
SPE2DR26FSQS0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26FSQS0 worth?
The government has obligated $17,915 on SPE2DR26FSQS0.
Is contract SPE2DR26FSQS0 an order under another contract?
Yes. SPE2DR26FSQS0 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQS0 competed?
The extent of competition for SPE2DR26FSQS0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award